Satellite Cross Roads,
Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. Recently, the group launched Exemptia, the world’s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only Indian pharma company to launch its own patented NCE – Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia. The group’s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group.
Zydus is one of the oldest players in the Indian formulations market. Besides continuously improving its market presence and market share, the group has also expanded its portfolio by entering newer therapeutic areas. The group has been launching new products with the first mover advantage and has a strong presence in both acute and chronic therapies. These strategic initiatives have helped Zydus become one of the dominant players in the Indian formulations market with the leadership position in several therapeutic categories. The group has built strong positions in key segments of Cardiovasculars, Gastrointestinals, Women’s Healthcare and holds leading positions in other therapeutic segments such as Respiratory, Dermatology, Pain Management and Anti-infectives.
The group’s Zydus Discovery is dedicated to marketing the innovative NCE therapy Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia. Zydus Biovation, a superspecialty division, markets the world’s first biosimilar of Adalimumab to treat inflammatory arthritis. This includes Rheumatoid Arthritis, Ankylosing’s spondylitis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis(JIA). Zydus BioNext also markets this therapy for other indications such as Crohn’s disease and Ulcerative Collitis.
New Chemical Entities:
The Zydus Research Centre is the dedicated NCE research arm of the Zydus Group. With its team of over 400 research professionals, ZRC spearheads the group’s quest of creating healthier and happier communities globally. Spread over an area of over 4,75,000 sq ft, ZRC is working on cutting edge technologies in 14 different scientific disciplines to discover novel therapeutic agents. The centre has capabilities to conduct drug discovery & development from concept to IND enabling preclinical and clinical studies.
Vaccine Technology Centre (VTC) is the vaccine research centre of the Zydus Group. VTC has two state-of-the-art R & D Centers, one located in Catania, Italy and the other in Ahmedabad, in the western part of India. Zydus Vaccine division has indigenously developed, manufactured and launched India’s first vaccine against H1N1 (Vaxiflu-S). The Vaccine Division’s Rabies Vaccine Manufacturing facility has received WHO pre-qualification, and is one of the largest Rabies manufacturing facility in India. The current programs under development include vaccine candidates designed to address infectious diseases like next-generation Influenza, Measles-Mumps-Rubella-Varicella, Typhoid, DPT-HiB, Hepatitis-B, Hepatitis-A, Hepatitis-E, Japanese Encephalitis, HPV and combination vaccines. Research is also focused on developing a Malaria vaccine.
In the Community:
Good health, happiness, joy, growth, togetherness, discovery, learning, exploration, evolution, transformation, aspirations, are all intrinsically linked with life. Zydus is dedicated to all these dimensions. Zydus Srishti, the group’s CSR programme, is about reaching out to make a difference in a myriad ways in the areas of Health – Swaasthya, Education – Shiksha, Research – Shodh and Outreach – Saath. Through these initiatives, the group reaches out to the community that it forms a part of, finding new expressions for its mission to create healthier communities globally. The group has forged meaningful partnerships with its key stakeholders both internal and external, partners in progress and the community at large. Ethical practices, accountability, robust governance and sustainable initiatives are at the very core of the group’s business strategy, planning and operations which helps minimise risks and leverage opportunities to create value. The group’s philosophy for community engagement is based on the principle of volunteerism and is an intensive, comprehensive and sustainable programme.
Krebs Biochemicals & Industries Limited
click above to visit
this company / organization